THYMIC CARCINOMA

This phase 2 trial tests the safety and effectiveness of avelumab, an immunotherapy drug, in people with thymoma or thymic carcinoma that has progressed after platinum-based chemotherapy. About 56 participants will receive avelumab intravenously every two weeks. The study aims to…

This phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinom…

This study tests a shorter, more intense radiation schedule (hypofractionation) given after complete surgical removal of thymic tumors. The goal is to see if it can prevent the cancer from coming back while causing fewer side effects than standard radiation. About 50 adults with …

This phase II trial tests bintrafusp alfa (M7824) in 9 adults with thymoma or thymic carcinoma that returned after platinum-based chemotherapy. Participants receive the drug intravenously every two weeks until their disease worsens or side effects become intolerable. The study ai…

This early-stage trial tests a new drug called HLX43, an antibody-drug conjugate that targets PD-L1, in people with advanced or metastatic solid tumors that have not responded to standard treatments. Participants also receive another immunotherapy drug, serplulimab (HLX10). The m…

This phase 2 trial is testing the immunotherapy drug nivolumab in 55 patients with type B3 thymoma or thymic carcinoma that has worsened after platinum-based chemotherapy. The main goal is to see if nivolumab can stop the cancer from growing for at least 6 months. Researchers wil…

This phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…

This study tested a combination of two drugs, pembrolizumab and sunitinib, in 9 people with advanced thymic cancer that had spread or could not be removed and had stopped responding to standard chemotherapy. The goal was to see if the combination could shrink tumors or stop them …

This study tested whether adding the targeted drug cetuximab to standard chemotherapy could shrink advanced thymoma or thymic carcinoma tumors before surgery. 18 adults with stage II to IVA disease received the combination, then had surgery to remove any remaining tumor. Research…

This study was designed to see if adding chemotherapy to radiation therapy after incomplete surgery for thymoma or thymic carcinoma could improve survival. It planned to enroll adults aged 18-75 who had incomplete tumor removal. However, the trial was withdrawn before any partici…

This research study collects blood, tumor tissue, and other body fluids from 1,000 adults with lung cancer, thymus cancer, or mesothelioma. The goal is to analyze these samples to find biological markers that could predict how the disease will progress or which treatments might w…